title: [Discrepant results of ABO type of red cells and serum in a patient with acute myelogenous leukemia].
abstract: A 42-year-old woman was admitted to our hospital with acute myelogenous leukemia. We conducted blood-type examination, and her serum showed strong agglutination with all B cells but questionable agglutination with A1 cells, which became stronger with incubation. We considered her blood type as O, but her previously assessed blood type was A. After receiving one cycle of induction therapy, she achieved complete remission and blood group A antigen was proven on her red blood cells. Anti-A1 in her serum disappeared after induction therapy. We should be aware that blood group antigens are not entirely independent of the environment and are occasionally modified by disease.
authors.affiliation: Department of Hematology, Yokohama City University Medical Center.
authors.forename: Atsuko
authors.initials: A
authors.lastname: Fujita
authors.forename: Shin
authors.initials: S
authors.lastname: Fujisawa
authors.forename: Rie
authors.initials: R
authors.lastname: Hyo
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Kuwabara
authors.forename: Etsuko
authors.initials: E
authors.lastname: Yamazaki
authors.forename: Naoto
authors.initials: N
authors.lastname: Tomita
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ishigatsubo
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001788:Blood Grouping and Crossmatching; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000188:drug therapy; D012074:Remission Induction
chemical_list: D000017:ABO Blood-Group System; D003561:Cytarabine; D003630:Daunorubicin